BioVie (BIVI) Expected to Announce Earnings on Monday

BioVie (NASDAQ:BIVI) is anticipated to release its Q3 2026 results after the market closes on Monday, May 11th. Analysts expect BioVie to post earnings of ($0.73) per share for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

BioVie (NASDAQ:BIVI) last released its quarterly earnings data on Friday, February 6th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.04.

BioVie Stock Up 1.6%

Shares of BioVie stock traded up $0.03 on Monday, hitting $1.71. The company’s stock had a trading volume of 84,417 shares, compared to its average volume of 91,085. BioVie has a 52-week low of $1.06 and a 52-week high of $13.20. The firm has a fifty day moving average price of $1.41 and a 200-day moving average price of $1.41. The company has a market capitalization of $12.87 million, a P/E ratio of -0.53 and a beta of 0.72.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in BIVI. Prelude Capital Management LLC acquired a new position in BioVie in the 3rd quarter valued at about $275,000. Prosperity Wealth Management Inc. acquired a new position in BioVie in the 3rd quarter valued at about $273,000. DRW Securities LLC acquired a new position in BioVie in the 4th quarter valued at about $149,000. Citadel Advisors LLC acquired a new position in BioVie in the 3rd quarter valued at about $199,000. Finally, Jane Street Group LLC acquired a new position in BioVie in the 2nd quarter valued at about $57,000. Institutional investors and hedge funds own 4.59% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioVie in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, BioVie currently has a consensus rating of “Sell”.

BioVie Company Profile

BioVie Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease.